StockData

Nexgel vs Sonoma Pharmaceuticals

NXGL and SNOA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NXGL and SNOA compare

Nexgel is the larger company, worth 9.3 times as much as Sonoma Pharmaceuticals ($37.0M against $4.0M).

Sonoma Pharmaceuticals grew revenue faster over the last twelve months (47.0% versus 3.4% for Nexgel).

Sonoma Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −10.3% compared with −51.3% at Nexgel.

Sonoma Pharmaceuticals scores higher on the StockData Score (11 against 6 for Nexgel), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNXGLSNOA
Size and price
Market cap$37.0M$4.0M
Share price$3.80$0.834
Change, 1 year−90.1%−75.7%
Change, 5 years–−99.2%
Beta (5Y)1.082.15
Employees19250
StockData Score
Total score611 (better)
Valuation score23 (better)
Growth score13 (better)
Performance score12 (better)
Health score23 (better)
Dividend score00
Valuation
P/S3.1×0.2× (better)
P/B7.5×0.6× (better)
FCF yield–−66.5%
Fair value$12.33$4.70
Margin of safety69.2%82.3% (better)
Growth
Revenue growth (TTM)3.4%47.0% (better)
Revenue growth, 5Y average76.1% (better)0.95%
Profitability
Gross margin35.1%38.9% (better)
Operating margin−44.8%−6.4% (better)
Net margin−51.3%−10.3% (better)
FCF margin–−12.1%
Return on equity−129%−42.5% (better)
Return on invested capital−91.0% (better)−112%
Financial health
Debt / equity0.090.02 (better)
Current ratio0.432.99 (better)
Altman Z-score−0.89 (better)−13.69
Piotroski F-score5 (better)3
Dividends and buybacks
Buyback yield–−99.2%
Shareholder yield0.00% (better)−99.2%
Ownership
Held by institutions9.0%2.3%
Held by insiders13.2%11.1%
Insider net buying, 12 months$721K–
Short interest, % of float–1.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.